MAVENCLAD® (cladribine tablets) has been recommended for listing on the Pharmaceutical Benefits Scheme (PBS) for relapsing remitting MS (RRMS), by the Pharmaceutical Benefits Advisory Committee (PBAC), subject to final approval by the Federal Health Minister.
Previously, MAVENCLAD® was registered for use in Australia by the Therapeutic Goods Administration (TGA), for the treatment of patients with RRMS, to reduce inflammation in the nervous system caused by MS.
Whilst the PBAC have recommended MAVENCLAD® for RRMS, its listing on the PBS is still subject to approval by the Federal Health Minister.
More information is available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/pbac-outcomes
Source document located here: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2018-07/positive-recommendations-07-2018.pdf (See page 5)
We will bring you any further information as we have it. Patients with queries should speak with their treating neurologist or contact our MSWA MS nurses on 9365 4888.